About Neon Therapeutics
Neon Therapeutics is a company based in Cambridge (United States) founded in 2015 was acquired by BioNTech in January 2020.. Neon Therapeutics has raised $161 million across 3 funding rounds from investors including Fidelity Investments, BioNTech and ArrowMark Partners. The company has 306 employees as of December 31, 2022. Neon Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Cambridge, United States
- Employees 306 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neon Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
$-79.78 M-4as on Dec 31, 2019
-
EBITDA
$-81.14 M-3as on Dec 31, 2019
-
Total Equity Funding
$161 M (USD)
in 3 rounds
-
Latest Funding Round
$36 M (USD), Series B
Dec 13, 2017
-
Investors
Fidelity Investments
& 12 more
-
Employee Count
306
as on Dec 31, 2022
-
Acquired by
BioNTech
(Jan 16, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Neon Therapeutics
Neon Therapeutics has successfully raised a total of $161M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $36 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $36.0M
-
First Round
First Round
(01 Oct 2015)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2017 | Amount | Series B - Neon Therapeutics | Valuation |
investors |
|
| Jan, 2017 | Amount | Series B - Neon Therapeutics | Valuation | PFM Health Sciences | |
| Oct, 2015 | Amount | Series A - Neon Therapeutics | Valuation | Access Industries , Clal Biotechnology Industries |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Neon Therapeutics
Neon Therapeutics has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, BioNTech and ArrowMark Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and holding company controlled by Len Blavatnik
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Global private equity investments are managed with long-term focus.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Neon Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Neon Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neon Therapeutics Comparisons
Competitors of Neon Therapeutics
Neon Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neon Therapeutics
Frequently Asked Questions about Neon Therapeutics
When was Neon Therapeutics founded?
Neon Therapeutics was founded in 2015.
Where is Neon Therapeutics located?
Neon Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Neon Therapeutics a funded company?
Neon Therapeutics is a funded company, having raised a total of $161M across 3 funding rounds to date. The company's 1st funding round was a Series A of $55M, raised on Oct 01, 2015.
How many employees does Neon Therapeutics have?
As of Dec 31, 2022, the latest employee count at Neon Therapeutics is 306.
What does Neon Therapeutics do?
Neon Therapeutics develops personalized vaccines and autologous T-cell therapies for cancer. It is based on research from the Dana Farber Cancer Institute, the Broad Institute and the Massachusetts General Hospital. The company has a proprietary platform for identifying targets through immune monitoring and epitope profiling. Their lead candidate, NEO-PV-01, is a personalized neoantigen vaccine for cancer that is being investigated for the treatment of melanoma, smoking associated NSCLC, and bladder cancer and is currently undergoing clinical development (Phase 1b trials) in combination with Opdivo. The company uses next-generation genomic sequencing, a proprietary computational pipeline (which identifies cancer mutations and determines which mutations are most likely to encode immunogenic neoantigens recognized on tumor cells) and an n1 manufacturing process to produce vaccines that specifically target individual patient tumors. In addition, Neon Therapeutics is also investigating targeted autologous T-cell therapies for other oncology investigations.
Who are the top competitors of Neon Therapeutics?
Neon Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Neon Therapeutics's investors?
Neon Therapeutics has 13 investors. Key investors include Fidelity Investments, BioNTech, ArrowMark Partners, Clal Biotechnology Industries, and Access Industries.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.